Nephrology has seen a revolution over the last decade with the discovery of multiple therapies to slow the progression of CKD and reduce cardiovascular disease burden. In addition to angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), there is trial-level
The perfect Smart Learning Animated GIF for your conversation. Discover and Share the best GIFs on Tenor.
Is Apolipoprotein E a new biomarker for DDD and C3GN? NSMC Intern Dr Jasmine Sethi decodes the recent study visually
This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
C3 glomerulopathy (C3G) is a rare disease resulting from dysregulation of the alternative pathway of complement. C3G includes C3 glomerulonephritis (C3GN) and dense deposit disease…
C3 glomerulopathy (C3G) is a rare disease resulting from dysregulation of the alternative pathway of complement. C3G includes C3 glomerulonephritis (C3GN) and dense deposit disease…
Is Apolipoprotein E a new biomarker for DDD and C3GN? NSMC Intern Dr Jasmine Sethi decodes the recent study visually
This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
PubMed® comprises more than 36 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text…
This week, we will discuss another IgA Nephropathy trial – Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.
